NewsBenzingaAgenus To Present Research On Botensilimab, Fc-Enhanced Multifunctional Anti-CTLA-4 Antibody, In Combination With Balstilimab, Anti-PD-1 Antibody, At SITC 2026 Agenus To Present Research On Botensilimab, Fc-Enhanced Multifunctional Anti-CTLA-4 Antibody, In Combination With Balstilimab, Anti-PD-1 Antibody, At SITC 2026 Benzinga 2026.10.02 13:03 (GMT+0) Open on Benzinga Other news Here’s How Much You Would Have Made Owning GE Aerospace Stock In The Last 5 Years Here's How Much $100 Invested In Allstate 15 Years Ago Would Be Worth Today Embedded AI evaluators won’t be an easy solution, Hugging Face’s policy chief says Zions Bancorp Q3 2026 Earnings Call Transcript Here’s How Much You Would Have Made Owning Baidu Stock In The Last 20 Years Inflation-Resistant Income Growth Machines Getting Too Cheap
